These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 36945447)
1. Plasma NT1-tau and Aβ Stern AM; Van Pelt KL; Liu L; Anderson AK; Ostaszewski B; Mapstone M; O'Bryant S; Petersen ME; Christian BT; Handen BL; Selkoe DJ; Schmitt F; Head E; medRxiv; 2023 Mar; ():. PubMed ID: 36945447 [TBL] [Abstract][Full Text] [Related]
2. Plasma NT1-tau and Aβ Stern AM; Van Pelt KL; Liu L; Anderson AK; Ostaszewski B; Mapstone M; O'Bryant S; Petersen ME; Christian BT; Handen BL; Selkoe DJ; Schmitt F; Head E; Alzheimers Dement; 2023 Dec; 19(12):5755-5764. PubMed ID: 37438872 [TBL] [Abstract][Full Text] [Related]
3. Dynamics of plasma biomarkers in Down syndrome: the relative levels of Aβ42 decrease with age, whereas NT1 tau and NfL increase. Mengel D; Liu W; Glynn RJ; Selkoe DJ; Strydom A; Lai F; Rosas HD; Torres A; Patsiogiannis V; Skotko B; Walsh DM Alzheimers Res Ther; 2020 Mar; 12(1):27. PubMed ID: 32192521 [TBL] [Abstract][Full Text] [Related]
4. NT1-Tau Is Increased in CSF and Plasma of CJD Patients, and Correlates with Disease Progression. Mengel D; Mok TH; Nihat A; Liu W; Rissman RA; Galasko D; Zetterberg H; Mead S; Collinge J; Walsh DM Cells; 2021 Dec; 10(12):. PubMed ID: 34944022 [TBL] [Abstract][Full Text] [Related]
5. Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers. Janelidze S; Christian BT; Price J; Laymon C; Schupf N; Klunk WE; Lott I; Silverman W; Rosas HD; Zaman S; Mapstone M; Lai F; Ances BM; Handen BL; Hansson O JAMA Neurol; 2022 Aug; 79(8):797-807. PubMed ID: 35789365 [TBL] [Abstract][Full Text] [Related]
6. Plasma NT1 Tau is a Specific and Early Marker of Alzheimer's Disease. Mengel D; Janelidze S; Glynn RJ; Liu W; Hansson O; Walsh DM Ann Neurol; 2020 Nov; 88(5):878-892. PubMed ID: 32829532 [TBL] [Abstract][Full Text] [Related]
7. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318 [TBL] [Abstract][Full Text] [Related]
13. Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease. Chen Z; Mengel D; Keshavan A; Rissman RA; Billinton A; Perkinton M; Percival-Alwyn J; Schultz A; Properzi M; Johnson K; Selkoe DJ; Sperling RA; Patel P; Zetterberg H; Galasko D; Schott JM; Walsh DM Alzheimers Dement; 2019 Mar; 15(3):487-496. PubMed ID: 30419228 [TBL] [Abstract][Full Text] [Related]
14. Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer's Disease. Lantero-Rodriguez J; Salvadó G; Snellman A; Montoliu-Gaya L; Brum WS; Benedet AL; Mattsson-Carlgren N; Tideman P; Janelidze S; Palmqvist S; Stomrud E; Ashton NJ; Zetterberg H; Blennow K; Hansson O Mol Neurodegener; 2024 Feb; 19(1):19. PubMed ID: 38365825 [TBL] [Abstract][Full Text] [Related]
15. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans. Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035 [TBL] [Abstract][Full Text] [Related]
16. Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. Janelidze S; Berron D; Smith R; Strandberg O; Proctor NK; Dage JL; Stomrud E; Palmqvist S; Mattsson-Carlgren N; Hansson O JAMA Neurol; 2021 Feb; 78(2):149-156. PubMed ID: 33165506 [TBL] [Abstract][Full Text] [Related]
17. Plasma P-tau181 and P-tau217 in Patients With Traumatic Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology. Asken BM; Tanner JA; VandeVrede L; Mantyh WG; Casaletto KB; Staffaroni AM; La Joie R; Iaccarino L; Soleimani-Meigooni D; Rojas JC; Gardner RC; Miller BL; Grinberg LT; Boxer AL; Kramer JH; Rabinovici GD Neurology; 2022 Aug; 99(6):e594-e604. PubMed ID: 35577574 [TBL] [Abstract][Full Text] [Related]
18. Plasma Total-Tau and Neurofilament Light Chain as Diagnostic Biomarkers of Alzheimer's Disease Dementia and Mild Cognitive Impairment in Adults with Down Syndrome. Petersen ME; Rafii MS; Zhang F; Hall J; Julovich D; Ances BM; Schupf N; Krinsky-McHale SJ; Mapstone M; Silverman W; Lott I; Klunk W; Head E; Christian B; Foroud T; Lai F; Diana Rosas H; Zaman S; Wang MC; Tycko B; Lee JH; Handen B; Hartley S; Fortea J; O'Bryant S; J Alzheimers Dis; 2021; 79(2):671-681. PubMed ID: 33337378 [TBL] [Abstract][Full Text] [Related]
19. Accelerated inflammatory aging in Alzheimer's disease and its relation to amyloid, tau, and cognition. Cullen NC; Mälarstig AN; Stomrud E; Hansson O; Mattsson-Carlgren N Sci Rep; 2021 Jan; 11(1):1965. PubMed ID: 33479445 [TBL] [Abstract][Full Text] [Related]
20. Association of β-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition. Tideman P; Stomrud E; Leuzy A; Mattsson-Carlgren N; Palmqvist S; Hansson O; Neurology; 2022 Apr; 98(15):e1525-e1533. PubMed ID: 35022305 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]